Introduction {#S1}
============

Allogeneic stem cell transplantation (allo-SCT) often remains the only curative treatment for hematological disorders. However, its success is frequently limited by acute and chronic graft-versus-host disease (GVHD), causing significant morbidity and mortality ([@B1]). One of the major challenges of allo-SCT is to reduce the incidence and severity of GVHD while boosting the graft-versus-leukemia (GVL) effect. In the setting of allo-SCT, the reconstitution of natural killer (NK) cells is of notable interest due to their known capability to induce GVL without GVHD ([@B2]). NK cells are known to play an important role in innate and adaptive immunity as well as in immunotherapeutic approaches ([@B3]--[@B5]). Recently, we could demonstrate that NK cells gain cytotoxic and cytokine producing functions early during hematopoietic immune reconstitution following autologous SCT ([@B6]). In addition to clinical studies, it has been shown in animal models that IL-2-activated NK cells may efficiently prevent or even reduce GVHD without any adverse impact on their important GVL effect ([@B7]--[@B9]). In humans, KIR mismatch in haploidentical BMT in the GVH direction reduced the risk of GVHD ([@B2], [@B10]), and adaptive cell therapies using expanded NK cells have been established for different malignancies and for the relapse of leukemia ([@B3], [@B5], [@B11], [@B12]).

However, NK cells are a heterogeneous population that can be classified into phenotypically and functionally distinct subsets ([@B9], [@B13], [@B14]). Recently, we demonstrated in a mouse allo-SCT and GVHD model that the mature subset of fully cytotoxic NK cells specifically mediates both the antitumor (GVL) and the GVHD-reducing effects ([@B9]).

In line with this finding, it is well known that NK cell reconstitution following allo-SCT correlates with higher numbers of immature CD56^high^CD16^dim^ NK cells that further differentiate into cytotoxic CD56^dim^CD16^high^ NK cells ([@B15]--[@B17]). While immune reconstitution *per se* has been shown to be influenced by the occurrence of acute graft-versus-host disease (aGVHD) and chronic GVHD and the need for immunosuppressive treatment ([@B18]), it is not yet completely known to which extent early NK cell reconstitution is influenced by the occurrence of aGVHD.

Here, in our single-center immune monitoring study performed at the University Hospital Regensburg, we investigated the possible correlation between the regeneration of NK cell subsets and the incidence of aGVHD during the first 200 days following allo-SCT, with a focus on immature NK cells (CD14^−^CD3^−^CD56^high^CD16^dim^), mature cytotoxic NK cells (CD14^−^CD3^−^CD56^dim^CD16^high^), and the ratio of these two populations (CD56^dim^:CD56^high^).

Materials and Methods {#S2}
=====================

Study Design and Sample Collection {#S2-1}
----------------------------------

This study was approved by the Ethics committee of the University Regensburg, Germany (approval no. 02/220) and carried out in accordance to the Declaration of Helsinki. All subjects gave written informed consent in accordance with the Declaration of Helsinki. In this study, data were collected from 2009 to 2012. In sum, 107 patients were included into this study. Patient characteristics are described in Table [1](#T1){ref-type="table"}. HLA typing was always performed with the same strategy using high resolution HLA-A, B, DR, and DQ for sibling and additional HLA-C typing for unrelated donors according to the standard of the European Federation for Immunogenetics.

###### 

**Patient's characteristics**.

  Characteristics                                    Total   With acute graft-versus-host disease (aGVHD)   Without aGVHD       *p*                            
  -------------------------------------------------- ------- ---------------------------------------------- ------------------- ------------------- ---- ----- ---------
  Patients                                           107     100                                            62                  100                 45   100   
  **Age at SCT**                                                                                                                                         *1*   
   Median (range), years                                                                                    52.7 (17.5--70.1)   50.3 (24.3--70.7)              
  **Sex**                                                                                                                                                      *0.013*
   Female                                            37      35                                             15                  24                  22   49    
   Male                                              70      65                                             47                  76                  23   51    
  **Disease**                                                                                                                                                  *0.133*
   ALL                                               10      9                                              8                   13                  2    4     
   AML                                               45      42                                             23                  37                  22   49    
   CLL                                               5       5                                              5                   8                   0    0     
   CML                                               1       1                                              1                   2                   0    0     
   Lymphoma                                          10      9                                              4                   6                   6    13    
   MDS                                               12      11                                             9                   15                  3    7     
   MM                                                19      18                                             10                  16                  9    20    
   Other                                             5       5                                              2                   3                   3    7     
  **Donor relation**                                                                                                                                           *0.191*
   Unrelated                                         77      72                                             48                  77                  29   64    
   Related sibling                                   30      28                                             14                  23                  16   36    
  **Donor HLA**                                                                                                                                                *0.443*
   Identical                                         88      82                                             49                  79                  39   87    
   Mismatched                                        19      18                                             13                  21                  6    13    
  **Stem cell source**                                                                                                                                         *0.627*
   BM                                                8       7                                              4                   6                   4    9     
   PBSC                                              98      92                                             57                  92                  41   91    
   CB                                                1       1                                              1                   2                   0    0     
  **Conditioning**                                                                                                                                             *0.130*
   RIC                                               86      80                                             46                  75                  40   89    
   MA                                                20      19                                             15                  25                  5    11    
  **Serotherapy**                                                                                                                                              
   ATG                                               58      54                                             35                  56                  23   51    
  **Graft-versus-host disease (GVHD) prophylaxis**                                                                                                             *0.927*
   CsA + MTX                                         84      79                                             48                  77                  36   80    
   CsA + MMF                                         19      18                                             12                  19                  7    16    
   Other                                             4       4                                              2                   4                   2    4     

*There were 107 patients included in this study. The distributions are shown for the underlying diseases, age, stem cell source, serotherapy, and GVHD prophylaxis. The p-value was determined using the Fisher-Exact test or the Mann--Whitney test, as appropriate*.

*SCT, stem cell transplantation; ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; MDS, myelodysplastic syndrome; MM, multiple myeloma; BM, bone marrow; PBSC, peripheral blood stem cells; CB, cord blood; RIC, reduced-intensity conditioning; MA, myeloablative; ATG, anti-thymocyte globulin; CsA, cyclosporin A; MTX, methotrexat; MMF, mycophenolate mofetil; p, p-value. p-Value was performed using the Fisher-Exact test or Mann--Whitney test as appropriate*.

Patient blood samples were collected prior to and following allo-SCT at different time points during regular outpatients visits. The frequency of sample collection was part of the individual follow-up plan for each patient at fixed time points and additionally when specific events occurred during the first 200 days after their treatment by allo-SCT. Exclusion criteria were the development of chronic GVHD or an overlap syndrome with signs of both acute and chronic GVHD.

Peripheral blood mononuclear cells of each sample were freshly isolated by density gradient centrifugation (Pancoll human, Pan-Biotech) and within 24 h analyzed by flow cytometry (FACS). Samples of healthy controls were processed in exactly the same way as patient samples. The following antibodies were used: CD3-FITC (SK7), CD16-PE (B73.1), CD14-PerCP (MΦP9), and CD56-APC (N-CAM 16-2), all from BD Biosciences. The focus of this analysis was on immature CD56^high^ and mature cytotoxic CD56^dim^ NK cells. At each time point, patients were considered to be "with aGVHD" or "without aGVHD" based on clinical findings. The evaluation of aGVHD was performed on a weekly basis applying the modified Keystone and NIH criteria ([@B19], [@B20]). All patients suffering from aGVHD, at least at one sample drawing, were included in the aGVHD group, those without any signs of aGVHD at any sampling time point were included in the group without aGVHD.

Statistical Considerations {#S2-2}
--------------------------

First, patient characteristics were summarized (Table [1](#T1){ref-type="table"}) and the Fisher-Exact test or Mann--Whitney test was used as appropriate for comparisons. Classification of GVHD was performed according to the NIH consensus criteria ([@B20]). Additionally, the cumulative incidence (CI) of aGVHD has been assessed considering relapse and death without relapse as competing event. In the same way, we analyzed the CI considering the grade of aGVHD.

With the aim to perform a longitudinal analysis of the NK cell numbers associated with aGVHD development and severity, a mixed effect regression model with a linear spline model was used. The reconstitution profile analyzed in this study comprised the dynamics of absolute values of NK cells, CD56^high^ cells, CD56^dim^ cells, and the ratio CD56^dim^ cells:CD56^high^ cells within the first 200 days after allo-SCT. Patients were previously classified into two groups according to their clinical and laboratory findings of aGVHD as described before. All measurements from patients who did not develop any signs of aGVHD at any collection time point measured during 200 days following allo-SCT were included in the longitudinal analysis. For patients who developed aGVHD during the 200 days period after allo-SCT, data measured from allo-SCT until achievement of aGVHD remission were included in the analysis. For each NK subset, the incidence of aGVHD and the severity of aGVHD were considered separately to be dependent variables. Furthermore, to evaluate the effect of steroid administration on NK cell reconstitution, the aGVHD patients were classified regarding GVHD stage and steroid treatment (ST) at each observation. Afterward, linear spline regression models were fitted separately for each NK cell subpopulation.

To optimize the residual distribution of the regression analysis, cell counts of NK subsets and the analyzed ratio were previously log~10~-transformed. Note that the statistical regression methods used here account for repeated measurements at different time points.

All statistical tests were two-sided with a significance level of 5% representing the 95% confidence interval. Data analysis was performed using the R software for statistical computing, version 3.1.1 (R Foundation for Statistical Computing, Vienna, Austria, <http://www.R-project.org/>). Figure [3](#F3){ref-type="fig"} was generated using GraphPad Prism 6 software, version 6.0.4.

Results {#S3}
=======

Patient Characteristics {#S3-1}
-----------------------

A total of 342 samples have been analyzed from 107 patients (78 prior to SCT, 264 after SCT), 37 (35%) females, and 70 (65%) males, were included in this study. Fifty-five (51%) patients suffered from acute leukemia, 19 (18%) from multiple myeloma, 12 (11%) from MDS, 10 (9%) from lymphoma, 6 from chronic leukemia (6%) and 5 from other diseases (5%), as shown in Table [1](#T1){ref-type="table"}. The majority of the patients underwent HLA-identical allo-SCT (*n* = 88, 82%). Thirty patients had related sibling donors (28%), 77 had unrelated donors (72%). The stem cell source was peripheral blood stem cells in 98 patients (92%), bone marrow (BM) in eight patients (7%), and cord blood in one patient (1%). A reduced-intensity conditioning (RIC) regimen was administered in 86 patients (80%), and 21 patients were treated using myeloablative regimens (20%). Fifty-eight patients received anti-thymocyte globulin treatment (54%). GVHD prophylaxis consisted of CSA + MTX in 84 patients (79%). Others received immunosuppressive monotherapy or individual combination treatments (see Table [1](#T1){ref-type="table"}). While 45 (42%) patients did not show signs of aGVHD, 62 (58%) patients developed aGVHD (grade 1: *n* = 22, grade 2: *n* = 21, grade 3: *n* = 14, grade 4: *n* = 5) at a median of day 28 (11--182) after allo-SCT. Symptoms that led to the classification of aGVHD and/or cGVHD were defined according to the NIH criteria as recently published ([@B20]).

No major difference in age, underlying disease, donor type, stem cell source, HLA match, conditioning regimen, and GVHD prophylaxis between the GVHD group and the group of patients without GVHD was observed. The only parameter contributing to a significant difference between the two mentioned groups was gender with a higher proportion of male patients in the GVHD group (*p* = 0.013).

The median age of the GVHD group was 52.7 years (17.5--70.1) and of the group of patients without signs of aGVHD 50.3 years (24.3--70.7). In both groups, the majority of patients suffered from AML (49%). Additional underlying diseases are indicated in Table [1](#T1){ref-type="table"}.

The median survival of the group that did not develop aGVHD was 34.1 months (ranging from 0.9 to 93.4 months), whereas the median survival of the GVHD group was 21.6 months (ranging from 1.2 to 65.7 months). The estimated CI of overall aGVHD was 57.9% (95% CI: 48.5--67.30%); the estimated CI for aGVHD grade I was 18.88% (95% CI: 11.42--26.34%), 19.73% (95% CI: 12.2--27.38%) for aGVHD grade II, 13.19% (95% CI: 6.75--19.64%) for aGVHD grade III, and 3.76% (95% CI: 0.68--8.78%) for severe aGVHD grade IV (Figure S1 in Supplementary Material). A critical phase with very high numbers of incidences occurred between days +25 and +50 after allo-SCT.

NK Cell Subsets {#S3-2}
---------------

A density plot gated on all CD56^+^CD3^−^CD14^−^ NK cells further distinguished two major subsets including immature CD56^high^CD16^dim^ (hereinafter referred to as CD56^high^) and mature cytotoxic CD56^dim^CD16^high^ NK cells (hereinafter referred to as CD56^dim^). In healthy adult controls, only 12.5 ± 9.6% of all NK cells belong to the immature CD56^high^ NK population whereas the majority of 83.1 ± 12.2% represents mature CD56^dim^ NK cells that coexpress CD16 (data not shown). Importantly, in our study cohort, there was no significant preexisting difference in NK cell subset distribution prior to allo-SCT among patients that later developed GVHD or not (Figure S2 in Supplementary Material). The appearance of immature CD56^high^ NK cells that do not yet express the Fcγ-receptor CD16 on their surface is indicative of an efficient immune reconstitution post-allo-SCT. In this study, following allo-SCT, the immature subset of CD56^high^ NK cells was highly increased and reached up to 45% of all NK cells in patients without aGVHD, but was significantly reduced in patients who developed aGVHD (Figure [1](#F1){ref-type="fig"}).

![**Definition of the CD56^high^CD16^dim^ and CD56^dim^CD16^high^ natural killer (NK) cell subsets**. Representative FACS dot plots of all CD56^+^CD3^−^CD14^−^ NK cells from a patient on day 24 post-allogeneic stem cell transplantation without (left) or from a patient on day 28 post-allo-SCT with (right) development of acute graft-versus-host disease.](fimmu-07-00595-g001){#F1}

Impact of aGVHD on NK Cell Reconstitution {#S3-3}
-----------------------------------------

Next, we addressed a possible impact of aGVHD on the NK cell numbers and early NK cell reconstitution throughout an observation period of 200 days after allo-SCT. Patients without any signs of aGVHD during the whole observation period had considerably higher NK cell numbers than patients who developed aGVHD, with significant differences in the CD56^high^ NK cell subset (Figure S2 in Supplementary Material). In contrast, there was only a trend of reduced numbers of CD4^+^ T cells around week 12 post SCT, but overall numbers of CD3^+^ T cells did not significantly differ in GVHD patients compared to patients without GVHD following allo-SCT (Figure S3 in Supplementary Material).

Moreover, as shown in Table [2](#T2){ref-type="table"}, the longitudinal analysis of the logarithmically transformed numbers of the different NK cell subsets revealed a negative association between the occurrence of aGVHD and the early expansion of the total NK cell population (*p* = 0.06), and in particular the CD56^high^ NK cell subset (*p* = 0.009). In contrast, there was no significant correlation between the CD56^dim^ NK cell subsets or the calculated ratio of CD56^dim^:CD56^high^ NK cells and aGVHD (Table [2](#T2){ref-type="table"}). Furthermore, a significant inverse correlation between the severity of aGVHD and the frequency of CD56^high^ NK cells during aGVHD could be demonstrated by the linear spline mixed effect model (Table [3](#T3){ref-type="table"}).

###### 

**Impact of aGVHD on immune reconstitution of NK cell subsets after allogeneic stem cell transplantation (allo-SCT)**.

                   Beta (SE)       *p*-Value
  ---------------- --------------- -----------
  **NK cells**                     
  aGVHD            −0.146 (0.08)   0.061
  **CD56^high^**                   
  aGVHD            −0.219 (0.08)   0.009
  **CD56^dim^**                    
  aGVHD            −0.114 (0.09)   0.194
  **Ratio**                        
  aGVHD            0.106 (0.07)    0.158

*The table summarizes the results of linear spline regression models with mixed effects analyzing the influence of aGVHD on each NK cell subset during the first 200 days after allo-SCT. The beta coefficients are given in log10 scale due to previous log10-transformed NK cell subsets*.

*NK cells, natural killer cells; CD56^high^, immature CD14^−^CD3^−^CD56^high^CD16^dim^ NK cells; CD56^dim^, mature CD14^−^CD3^−^CD56^dim^CD16^high^ NK cells; Ratio, ratio CD56^dim^:CD56^high^; aGVHD, acute graft-versus-host disease; Beta, beta coefficient*.

###### 

**Impact of the aGVHD grade on the number of CD56^high^ natural killer (NK) cells**.

  CD56^high^        Beta (SE)      *p*-Value
  ----------------- -------------- -----------
  aGVHD grade 1     0.007 (0.11)   0.94
  aGVHD grade II    −0.28 (0.10)   0.008
  aGVHD grade III   −0.48 (0.12)   \<0.001
  aGVHD grade IV    −0.43 (0.16)   0.009

*The table shows the beta coefficients and corresponding p-values for each aGVHD grade with respect to the reference category without aGVHD from a mixed effect regression with a linear spline model. Patients with aGVHD grade III or IV showed a significantly lower frequency of CD56^high^ NK cells compared to patients with aGVHD grade I or II*.

*aGVHD, acute graft-versus-host disease; Beta, beta coefficient*.

Figure [2](#F2){ref-type="fig"} shows the recovery of the CD56^high^ NK subset in patients without signs of aGVHD (solid black line) compared to patients with aGVHD (dashed black line) and their corresponding 95% confidence intervals. We observed significantly lower numbers of CD56^high^ NK cells in the aGVHD group, suggesting that aGVHD might cause impaired CD56^high^ NK cell regeneration in the early phase after allo-SCT.

![**Association of acute graft-versus-host disease (aGVHD) and the immune recovery of CD56^high^ natural killer (NK) cells**. Lines represent the back-transformed CD56^high^ NK cell numbers estimated from the model. The solid line shows the cell recovery in patients without aGVHD, and the dashed line indicates patients with aGVHD and the corresponding 95% confidence interval (left graphic). A fitted model considering aGVHD severity illustrates a significant correlation between aGVHD grade and the lower recovery of CD56^high^ NK cells during aGVHD (right graphic). \*\**p* \< 0.01, \*\*\**p* \< 0.001.](fimmu-07-00595-g002){#F2}

Furthermore, the reconstitution of the CD56^high^ subpopulation was analyzed with regard to the severity of aGVHD. We observed a significant correlation between the grade of aGVHD and the degree of disturbance of CD56^high^ NK cell reconstitution (Figures [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}). There was almost no difference in NK cell immune reconstitution between patients with grade I GVHD and those without GVHD. In contrast, patients with severe grade of aGVHD (III--IV) showed lower numbers of CD56^high^ NK cells in comparison to patients with milder forms of aGVHD. In summary, not only the occurrence but also the severity of aGVHD correlated with a delayed reconstitution of the CD56^high^ NK cell subset.

![**Impact of steroid application on natural killer (NK) cell subset distribution**. Linear spline model including all patients that developed acute graft-versus-host disease at least at one measurement during the entire observation period after allogeneic stem cell transplantation (allo-SCT). All NK cell data were classified into four categories according to the stage of graft-versus-host disease (GVHD) (before or during/after GVHD) and the treatment with steroids \[steroid treatment (ST) or no ST\]. The bars illustrate the frequency of each NK cell subset related to the respective estimate regression coefficients for that specific subset compared to that of patients before GVHD development and without ST (100% reference). \**p* \< 0.05, and \*\*\**p* \< 0.001. Ψ related to estimated coefficients.](fimmu-07-00595-g003){#F3}

Impact of Steroids {#S3-4}
------------------

To elucidate the impact of steroid treatment (ST) on NK cell recovery, the frequencies of the different NK cell subpopulations have been calculated for all patients who developed aGVHD at least at one sampling time during the entire observation period of 200 days (Figure [3](#F3){ref-type="fig"}). All data on the NK cell numbers measured in these GVHD patients have been classified and analyzed according to the stage of disease at the given time point, as being obtained either before or during development of GVHD and with or without ST. Reasons for ST without occurrence of GVHD were in most cases inappetence, nausea, gastroenteritis, and weakness treated with moderate dosing of prednisolone. Only few patients received high dose prednisolone due to, e.g., a severe capillary leak, vasculitis, or ARDS. GVHD patients were also treated with prednisolone (1 mg/kg BW).

Figure [3](#F3){ref-type="fig"} and Table S1 in Supplementary Material show the results of the linear regression model with smoothing spline performed with the above mentioned disease and treatment classifications of all GVHD patients. All results are shown in relation to measurements at time points without signs of aGVHD and without ST that served as base line (=100%) of each individual patient. In sum, we observed an additive impact of steroids and aGVHD on reconstitution of NK cell subsets. Of note, based on these analysis, we can exclude that the before mentioned negative impact of aGVHD on the CD56^high^ subpopulation recovery could be completely explained by ST.

Discussion {#S4}
==========

The complex interplay of NK cells and NK cell subsets with other immune cells in the development of aGVHD following allo-SCT has mainly been investigated in different animal models, but only very few human studies have addressed NK cells thus far ([@B8], [@B9], [@B15]--[@B17], [@B21]).

However, following allo-SCT, NK cells are among the first lymphocytes to reconstitute and reach normal numbers after 1--4 months, independent of the stem cell source ([@B17], [@B19], [@B22], [@B23]).

In line with our previous preclinical observation that NK cell maturation was impaired in mice suffering from aGVHD and that only the subset of mature CD11b-expressing NK cells efficiently protects from developing aGVHD in a mouse model of allogeneic BMT ([@B9]), Podgorny et al. investigated a large patient cohort and observed a reduction in the number of total and cytotoxic NK cells during aGVHD ([@B15]). This effect might be due to a GVHD-induced destruction of the hematopoietic niche in the BM as demonstrated by the effect on B cell reconstitution ([@B24], [@B25]). However, this study did not address the impact of aGVHD on early NK cell reconstitution.

Notably, NK cells play an important role in the early innate immune defense, and a recent report has shown an association of the reduced number of total and CD56^high^ NK cells with postengraftment infection rates after allo-SCT ([@B26]).

In our study, we analyzed 342 samples of 107 patients before and after allo-SCT for a possible association between aGVHD and NK cell numbers including subset composition at different time points during the first 200 days following allo-SCT.

To our knowledge, our data are the first to demonstrate that aGVHD correlates not only with reduced numbers of total NK cells but specifically with the disturbed regeneration of CD56^high^ NK cells early after allo-SCT. Patients without any aGVHD during the whole observation period had a higher number of NK cells and specifically the CD56^high^ NK cell subset than patients who developed aGVHD (Table [2](#T2){ref-type="table"}; Figure S2 in Supplementary Material), while T cell numbers did not significantly differ (Figure S3 in Supplementary Material).

Furthermore, we performed a longitudinal analysis to investigate the impact of aGVHD on early NK cell reconstitution (Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}). Remarkably, we found a significant correlation between the severity of aGVHD and the degree of disturbance of CD56^high^ NK cells during aGVHD (Figure [2](#F2){ref-type="fig"}; Table [3](#T3){ref-type="table"}). As described before ([@B15]), we also found a non-significant trend toward a decrease in total and cytotoxic CD56^dim^ NK cells. A possible explanation for differences in comparison to other studies might be the study design and classification of patients according to severity of aGVHD ([@B27]).

In summary, our data suggest a negative impact of aGVHD on early NK cell reconstitution and maturation resulting in a disturbed NK cell subset composition. Interestingly, these developments seemed to take place regardless of the immunosuppressive effect of ST (Figure [3](#F3){ref-type="fig"}; Table S1 in Supplementary Material). Of note, it cannot be excluded that negative effects of steroids on NK cell reconstitution might influence the risk of GVHD post-allo-SCT.

The most probable cause for the delayed NK recovery is a lymphocyte maturation defect in the BM niche. However, it still remains unclear if the reduced number of NK cells is the underlying cause or a consequence of aGVHD. Mouse experiments suggest that mature NK cells might be capable of protecting from aGVHD by inhibition of allogeneic T cell proliferation, either directly by perforin-mediated killing of T cells or indirectly by lysis of antigen presenting host cells that support T cell lysis ([@B8], [@B9]). However, it should be taken into account that this effect was observed in a HLA-mismatched situation while the presented data relate to HLA-matched transplantation. In patients, a significant decline in the number of CD56^high^ NK cells early after allo-SCT might even be a predictive parameter for the development of aGVHD. However, this statement remains hypothetical as we did not have enough measurements of the patients CD56^high^ NK cell numbers shortly before the appearance of first GVHD signs that allowed the statistical evaluation in this context.

Therefore, further studies are needed to unravel the value of NK cell numbers as biomarker of aGVHD as well as the pathophysiology of the impaired NK cell regeneration that might be caused by a GVHD-induced destruction of the hematopoietic niche in the BM or a lack in hematopoietic growth factors.
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